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Paricalcitol versus calcitriol in the treatment of secondary hyper- Osteitis fibrosa cystica, resulting from poorly con-
parathyroidism. trolled secondary hyperparathyroidism, remains a com-
Background. Management of secondary hyperparathyroid- mon manifestation of renal osteodystrophy and causesism has included the use of active vitamin D or vitamin D ana-
significant morbidity in patients with chronic renal fail-logs for the suppression of parathyroid hormone (PTH) secre-
ure [1, 2]. Decreased renal production of calcitriol (1,25tion. Although, these agents are effective, therapy is frequently
limited by hypercalcemia, hyperphosphatemia, and/or eleva- vitamin D3), hypocalcemia, and hyperphosphatemia are
tions in the calcium-phosphorus (Ca  P) product. In clinical the major contributing factors to the development of
studies, paricalcitol was shown to be effective at reducing PTH
secondary hyperparathyroidism [1, 3–5]. Calcitriol is syn-concentrations without causing significant hypercalcemia or
thesized from previtamin D3 by hydroxylation on carbonshyperphosphatemia as compared to placebo. A comparative
study was undertaken in order to determine whether paricalci- 25 and 1 in the liver and kidney, respectively [6]. The
tol provides a therapeutic advantage to calcitriol. administration of calcitriol decreases the synthesis and
Methods. A double-blind, randomized, multicenter study secretion of parathyroid hormone (PTH) directly by in-comparing the safety and effectiveness of intravenous pari-
hibition of the synthesis of PTH at the pre-promessengercalcitol and calcitriol in suppressing PTH concentrations in
hemodialysis patients was performed. A total of 263 random- RNA level [4] and indirectly by both increasing the se-
ized patients were enrolled at domestic and international sites. rum calcium concentration and by increasing the sensitiv-
Following the baseline period, patients with serum Ca P 75, ity of PTH suppression to calcium.and a PTH level 300 pg/mL were randomly assigned to re-
Both oral and parenteral forms of calcitriol have beenceive either paricalcitol or calcitriol in a dose-escalating fashion
effective in treating and preventing secondary hyperpara-for up to 32 weeks. Dose adjustments were based on laboratory
results for PTH, calcium, and Ca  P. The primary end point thyroidism [8–11]. However, in the United States, intrave-
was the greater than 50% reduction in baseline PTH. Second- nous calcitriol has been more widely used and thought to
ary end points were the occurrence of hypercalcemia and ele-
be the more effective form. Serum calcium concentrations,vated Ca  P product.
however, are increased via vitamin D–enhanced intestinalResults. Paricalcitol-treated patients achieved a 50% re-
duction from baseline PTH significantly faster than did the cal- calcium absorption and increased mineral resorption from
citriol-treated patients (P 0.025) and achieved a mean reduction bone [3, 7], thereby increasing serum calcium concentra-
of PTH into a desired therapeutic range (100 to 300 pg/mL) at tions, which occasionally results in hypercalcemia. Cal-approximately week 18, whereas the calcitriol-treated patients,
citriol, especially in conjunction with calcium-containingas a group, were unable to achieve this range. Moreover, pari-
calcitol-treated patients had significantly fewer sustained epi- phosphate binders, greatly increases the risk for hyper-
sodes of hypercalcemia and/or increased Ca  P product than calcemia, hyperphosphatemia, and increased calcium-
calcitriol patients (P  0.008). phosphorus (Ca P) product as well as the developmentConclusion. Paricalcitol treatment reduced PTH concentra-
of adynamic bone disease [12–16]. These disturbances, intions more rapidly with fewer sustained episodes of hypercalce-
turn, can result in soft tissue and vascular calcifications,mia and increased Ca  P product than calcitriol therapy.
which contributes to increased mortality and cardiovas-
cular morbidity [17–19].Key words: paricalcitol, calcitriol, ESRD, secondary hyperparathyroid-
ism, hemodialysis, hypercalcemia, hyperphosphatemia. Thus, current clinical practice is focused on developing
therapies that do not cause increased body burdens ofReceived for publication February 6, 2002
calcium and phosphorus. This has included the use of aand in revised form September 24, 2002, and October 28, 2002
Accepted for publication November 21, 2002 noncalcium-containing phosphate binder, sevelamer hy-
drochloride, a hydrogel of cross-linked poly-allylamine 2003 by the International Society of Nephrology
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Table 1. Dose administration schedule
Dose adjustmentsa
Treatment Initial dose Increments Escalation Maximum dose Reductionb
Paricalcitol 0.04 /kg 0.04 g/kg 4-week intervals 0.24 g 1-week intervals
Calcitriol 0.01 /kg 0.01 g/kg 4-week intervals 0.06 g 1-week intervals
a Dose adjustment criteria were met prior to changes in study drug dosing. All doses, including the initial dose, were to be maintained for a minimum of 4 weeks
unless safety parameters were met.
b Unless immediate reduction was necessary for safety reasons
hydrochloride [20], as well as analogs of calcitriol that not previously been enrolled in a paricalcitol trial were
have less effect on the absorption of calcium and phos- eligible for enrollment. Subjects were excluded if any of
phorus. One such analog, 19-nor-1, 25-dihydroxyvitamin the following conditions existed: (1) screening PTH
D2 (paricalcitol), was approved for clinical use in hemo- value 250 pg/mL or 300 pg/mL if naı¨ve to vitamin D
dialysis patients in 1998. Preclinical studies with parical- therapy, (2) screening calcium value of 11.5 mg/dL,
citol have demonstrated significant PTH suppression, (3) screening Ca  P of greater than 70, (4) history of
comparable to that observed with intravenous calcitriol. clinically significant allergic reaction to calcitriol or other
Early studies evaluating paricalcitol dosing suggested vitamin D compounds, or (5) necessity for calcitonin,
that for comparable suppressive effects, paricalcitol maintenance oral or intravenous glucocorticoids, or
should be dosed at a ratio of 4:1 to calcitriol [21]. How- other drugs that could have affected calcium or bone
ever, a recently published study of dialysis patients resis- metabolism, other than females on stable estrogen
tant to calcitriol found that a more appropriate dosing and/or progestin therapy. All clinical laboratories were
ratio of paricalcitol to calcitriol would be 3:1 [22]. Never- performed in a central laboratory (Covance Central Lab-
theless, in contrast to what has been observed with oratory Services, Indianapolis, IN, USA). All intact PTH
calcitriol, paricalcitol seems to exhibit less of a calcemic measurements were performed at Covance (Covance
and phosphatemic effect with a reduction in parathyroid Central Laboratory Services) using the Nichols immu-
gland size and beneficial effects on bone remodeling in noradiometric assay (IRMA). The Institutional Review
experimental studies [23–26]. Board at each center approved the protocol and consent
In clinical studies, paricalcitol was shown to be effec- form. Informed consent was obtained from each subject
tive at reducing PTH concentrations without causing sig- prior to enrolling into the study.
nificant hypercalcemia or hyperphosphatemia as com- The study consisted of a pretreatment (washout/base-
pared to placebo [21]. In order to determine whether line) phase and a treatment phase. During pretreatment,
paricalcitol provides a therapeutic advantage to calcitriol, patients receiving calcitriol (intravenous or oral), dihydro-
a double-blinded, randomized multicenter comparative tachysterol, calcidol, or calcitonin prior to enrollment
study was undertaken. A preliminary report of our re- underwent a 2-week washout period which was followed
sults from a subset of patients enrolled in this study at by a 2- to 6-week baseline period. Weekly measurements
two dialysis centers affiliated with Northwestern Univer- of serum calcium, phosphorous, albumin, and PTH concen-
sity was recently published [27]. trations were performed and final adjustments to pertinent
medications (i.e., phosphate binders and dialysate calcium
concentration) were made in order to maintain these medi-METHODS
cines as constant as possible during the study. PatientsTo compare the safety and effectiveness of intravenous
not receiving calcitriol, dihydrotachysterol, –calcidol, orparicalcitol with intravenous calcitriol in suppressing
calcitonin prior to enrollment directly entered the base-PTH in end-stage renal disease (ESRD) patients under-
line period. Following the pretreatment phase, patientsgoing chronic hemodialysis, a phase III, prospective, com-
with normalized total serum calcium concentration11.5parative, double-blind, randomized, multicenter study was
mg/dL, serum Ca P	 75, and a PTH level300 pg/mLconducted during the years 1995 and 1996. The primary
were randomized to receive either paricalcitol or cal-efficacy goal was the achievement of a 50% reduction
citriol for the treatment phase. The treatment phasein baseline PTH levels. Safety end points were to evalu-
lasted 12 to 32 weeks and subjects were dosed in a 4:1ate the occurrence of hypercalcemia and/or elevated
ratio of paricalcitol to calcitriol as shown in Table 1.Ca  P in these patients. Hypercalcemia was defined as
Doses were escalated every 4 weeks up to a maximuma normalized serum total calcium 11.5 mg/dL and an
of five dose escalations. Patients were dose titrated toelevated Ca P was defined as being75. All medically
achieve at least a 50% reduction in PTH concentrationstable adult ESRD patients undergoing chronic hemodi-
alysis three times a week for at least 6 months who had into a clinically appropriate range (100 pg/mL). The
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Table 2. Dose adjustment criteria
Dose maintained Dose increased Dose reduced
PTH 100 pg/mL Minimum of 4 weeks at the given dose PTH100 pg/mL after 2 consecutive weeks
of treatment on a given dose level
-and- -and- -or-
PTH level reduced 50% from baseline PTH level did not decrease 50% Calcium is 11.5 mg
-and- -or- -or-
Calcium is 	11.5 mg/dL If the PTH level had previously been reduced 50% All Ca  P levels in a consecutive 2-week
has subsequently increased and is no longer less than period at a given dose level are 75
50% of baseline.
-and- -and-
At least one Ca  P within the preceding Calcium is 	11.5 mg/dL
consecutive 2-week period is 	75 -and-
At least one Ca  P within the preceding consecutive
2-week period is 	75
PTH is parathyroid hormone.
“maintenance” dose was defined as the dose whereby a independent variable was treatment. Patients who did
patient’s PTH was reduced by 50% from baseline (or not meet the end point prior to study end or were prema-
was the fifth dose escalation, whichever occurred first). turely terminated were censored at their last day of treat-
The dose would be reduced if PTH levels decreased to ment. The log-rank test was used to test for the equality
less than 100 pg/mL, or if Ca  P became greater than of survival curves between treatments.
75 for 2 consecutive weeks, or if a single episode of A total of 100 patients per treatment group were re-
serum calcium greater than 11.5 mg/dL occurred. Once quired to detect a 15% difference between the two treat-
a patient reached the maintenance dose via the dose ment groups in the proportions of patients experiencing
adjustment criteria, the patient was to remain at that at least one incidence of hypercalcemia and/or an ele-
dose for 12 weeks provided all the maintenance criteria vated Ca  P  75 during the study, with an  level of
continued to be met (Table 2). This 12-week period 5% and a power of 80%. This assumed a 10% incidence
was an attempt to allow for equivalent treatment of the rate in the paricalcitol treatment group and a 25% inci-
disease through PTH reduction for both treatment dence rate in the calcitriol treatment group.
groups. Ca  P levels were measured twice weekly,
whereas PTH concentrations were assessed weekly. In-
vestigators were instructed to maintain phosphate binder RESULTS
usage, which was predominantly calcium carbonate or After providing consent to participate, a total of 476
acetate (sevelamer HCL was not yet available), as con- patients were enrolled at 27 centers in the United States,
stant as possible (chronic use of phosphate binders con- The Netherlands, Spain, and Switzerland. A total of 266
taining aluminum was not permitted), and centers were subjects met eligibility criteria and were randomized to
required to maintain calcium concentration in the dialy- treatment with either paricalcitol or calcitriol. Baseline
sate bath at 2.5 mEq/L. characteristics are presented in Table 3. There were no
differences between groups with respect to gender, race,Statistics
age, history of prior vitamin D exposure, length of timeAll analyses were performed with SAS version 6.12
on dialysis, and major causes of chronic renal failure.(SAS Institute, Cary, NC, USA) procedures GLM, FREQ,
Baseline values for PTH, calcium, phosphorus, and albu-LIFETEST, MEANS, and UNIVARIATE (SAS Insti-
min were also comparable between treatment groups.tute, Inc., Cary, NC, USA). All statistical tests were two-
A decrease in mean PTH concentrations was observedtailed and P values 	0.050 were considered statistically
in both treatment groups (Fig. 1). The primary treatmentsignificant.
goal was to achieve a 50% reduction in baseline PTHA Fisher’s exact test was used to test for a difference
levels. A mean reduction from baseline PTH concentra-in incidence rates for categorical variables with a dichot-
tion of50% was achieved at week 15 in the paricalcitolomous outcome. A one-way analysis of variance was
group compared to week 23 in the calcitriol-treated sub-used to test for a difference between treatment groups
jects. Thus, paricalcitol dosed at a 4:1 ratio to calcitriolin continuous variables such as the change from baseline
resulted in a more rapid decrease in PTH concentrations.in laboratory variables and vital signs. The Kaplan-Meier
PTH concentrations between 100 and 300 pg/mL aremethod of generating survival curves was used to evalu-
considered a desirable therapeutic range for patientsate the time (in days) to the first occurrence of four
consecutive 50% decreases from baseline in PTH. The with ESRD. Subjects receiving paricalcitol achieved this
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Table 3. Baseline patient characteristics creased Ca  P product are the major limitations to
effective vitamin D therapy, the incidence of hypercalce-Paricalcitol Calcitriol
(N  130) (N  133) mia and/or elevated Ca  P (75) during the treatment
Male 70 (54%) 80 (60%) phase was analyzed. No significant differences were ob-
Female 60 (46%) 53 (40%) served between treatment groups in the proportions of
Race
patients who became hypercalcemic and/or experiencedCaucasian 34 (26%) 40 (30%)
African American 81 (62%) 76 (57%) elevated Ca  P at least once during treatment (Table
Other 15 (12%) 17 (13%) 4). However, on further analysis, the incidence of hyper-
Age (mean
SD) 56.7
15.5 56.6
14.3
calcemia and/or Ca P 75 for two consecutive labora-Previous vitamin D therapya
Oral calcitriol 28 (22%) 30 (23%) tory draws and the incidence of hypercalcemia and/or
Oral dihydrotachysterol 2 (2%) 2 (2%) Ca  P  75 for four consecutive laboratory draws was
Intravenous calcitriol 87 (67%) 90 (68%)
significantly lower in the paricalcitol group compared toOther vitamin D analogues 10 (8%) 3 (2%)
No vitamin D analogues 22 (17%) 21 (16%) the calcitriol group (18% vs. 33%) (P  0.008). There
Duration of dialysis years was no difference in the incidence of hyperphosphatemia
Less than 1 year 31 (24%) 32 (24%)
between treatment groups.One year but less than 5 years 58 (45%) 53 (40%)
Five years but less than 10 years 21 (16%) 39 (29%) Treatment outcomes are further illustrated through
Ten years or longer 20 (15%) 9 (7%) group comparison of the total days on study drug relative
PTH (mean
SE) pg/mL 648
30.5 675
35.0
to PTH suppression. Despite a disparity of 1600 pa-Calcium (mean
SE) mg/dL 9.0
0.08 9.0
0.09
Phosphorous (mean
SE) mg/dL 5.9
0.12 5.8
0.13 tient-treatment days and similar PTH values at baseline,
Albumin (mean
SE) g/dL 3.6
0.04 3.6
0.03 patients in the paricalcitol treatment group achieved a
a A patient may have received one, more than one, or no previous vitamin D greater number of days in the optimal therapeutic range
treatment
(100 to 300 pg/mL) than patients receiving calcitriol (Ta-
ble 5). Furthermore, paricalcitol patients experienced
fewer episodes of hypercalcemia, fewer incidences of
PTH range by week 18, whereas calcitriol-treated sub- elevated Ca  P, and a greater incidence of decreased
jects never achieved this “therapeutic” range. Ca  P product (50) than subjects receiving calcitriol
The graph of mean percent change from baseline in while in the optimal PTH therapeutic range.
PTH over time indicated that paricalcitol reduces PTH As a marker for bone remodeling activity, alkaline
levels more rapidly than calcitriol. To further validate phosphatase activity provides an additional efficacy vari-
this observation, the number of days to the first period of able. Mean reductions in total alkaline phosphatase were
four consecutive values consistent with a 50% reduction observed for both treatment groups. At week 16 of the
from baseline in PTH levels (event) was analyzed by the treatment phase, mean reductions from baseline ob-
Kaplan-Meier method of survival analysis. Figure 2 shows served were 26.3 U/L in the paricalcitol group (N  91)
estimates over time of the proportions of all-treated pa- and 27.3 U/L in the calcitriol group (N  84). At follow-
tients not yet attaining a period of four consecutive val- up, mean reductions from baseline observed were 37.4
ues consistent with a50% reduction from baseline PTH U/L in the paricalcitol group (N  122) and 44.0 U/L
levels. The median number of days to the event was sig- in the calcitriol group (N  115). The safety profiles
nificantly less (P  0.025) for the paricalcitol group (87 presented during the study by each compound were com-
days) compared to the calcitriol group (108 days). parable. No meaningful differences were observed be-
The treatment groups were also evaluated by analyz- tween treatment groups in the incidence, severity, or
ing the proportions of subjects achieving a50% reduc- relationship of adverse events occurring during treat-
tion from baseline in PTH levels: (1) at least once during ment. Similarly, other laboratory values (change from
treatment; (2) for one or more periods of four consecu- baseline) and vital signs assessments were comparable.
tive PTH laboratory draws; and (3) at the final laboratory
draw. More than 80% of all-treated subjects in each
DISCUSSIONtreatment group achieved a50% reduction from base-
Previous clinical studies of paricalcitol have demon-line in PTH levels at least once during treatment. A
strated its effectiveness and safety in reducing PTH con-slightly higher proportion of subjects in the paricalcitol
centrations in patients with moderate to severe hyper-group achieved a 50% decrease in PTH for at least one
parathyroidism [21, 28]. This study is the first blinded,period of four consecutive laboratory draws (paricalcitol
randomized, multicenter clinical trial comparing a vita-62%, calcitriol 54%). In total, approximately 60% of
min D analog with calcitriol, and shows that paricalcitol,patients in each treatment group achieved a 50% re-
dosed at a 4:1 ratio to calcitriol, results in a greaterduction from baseline in PTH levels at the final blood
and more rapid decrease in PTH concentrations thandraw. These results were not significantly different.
Since hypercalcemia, hyperphosphatemia and/or in- calcitriol (Figs. 1 and 2). The rapid decrease in PTH is
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Fig. 1. Mean parathyroid hormone (PTH)
(
SEM) during the 32 weeks of drug adminis-
tration. Paricalcitol patients (solid line) experi-
enced a more rapid reduction over time in mean
PTH levels, resulting in more days in the effec-
tive therapeutic range (100 to 300 pg/mL) than
patients in the calcitriol treatment group (whose
mean values did not enter this target range).
Fig. 2. Kaplan-Meier curves to first period of
four consecutive values consistent with a50%
reduction from baseline in parathyroid hor-
mone (PTH) levels. Patients in the paricalcitol
treatment group achieved the first of four con-
secutive 50% reductions from baseline PTH
levels in a median of 87 days compared to 108
days for calcitriol patients. All-treated patients,
paricalcitol (N  130), calcitriol (N  133).
The significance of this difference (P 0.025)
attests to the rapidity of overall PTH reduc-
tion for patients treated with paricalcitol.
Table 4. Incidence of hypercalcemia and elevated Ca  P
Number (%) of patients
Calcitriol Paricalcitol
End point (N  133) (N  130) P valuea
Hypercalcemic and/or a Ca  P  75 at least once during treatment 90 (68%) 83 (64%) 0.519
Hypercalcemic and/or a Ca  P  75 for at least two consecutive blood draws 67 (50%) 50 (38%) 0.034
Hypercalcemic for at least two consecutive blood draws and/or a Ca  P  75
for at least one period of four consecutive blood draws 44 (33%) 24 (18%) 0.008
a P values comparing the proportions between treatment groups are from a 2  2 Fisher’s Exact Test.
similar to what we observed when we analyzed a sub- in which the percentage of subjects experiencing severe
hyperphosphatemia (serum phosphorus greater than 8.0group of 38 subjects from a single center [27].
Furthermore, in the present study a higher proportion mg/dL) was higher in the subjects receiving calcitriol
compared to those receiving paricalcitol [27], the occur-of the paricalcitol-treated patients achieved a mean PTH
concentration in the clinically desirable target range of rence of hyperphosphatemic episodes was comparable in
both groups. Although persistent hypercalcemia and/or100 to 300 pg/mL (Table 5). By reducing serum concen-
trations of PTH more rapidly than calcitriol, paricalcitol elevated Ca P product was observed less in the parical-
citol group (Table 4) in this multicenter analysis. Themay offer an important clinical advantage to calcitriol.
Unlike the findings in our previous subgroup analysis, difference in incidence of hyperphosphatemia and hyper-
Sprague et al: Paricalcitol vs. calcitriol in secondary hyperparathyroidism1488
Table 5. Calcium, phosphorus, and Ca  P levels relative to days on study drug and overall parathyroid hormone (PTH) suppression
Paricalcitol Calcitriol
(N  130) (N  133)
Total days on study drug 16,030 17,718
Total days of PTH suppression (target range of 100 to 300 pg/mL) 4505 4269
Percent of time in target range 28.1 24.1
Incidences of hypercalcemia while PTH suppressed (per 1000 patient-day) 30 (6.7) 39 (9.2)
Number of patients who became hypercalcemic while PTH suppressed 13 19
Incidences of hyperphosphatemia while PTH suppressed (per 1000 patient-day) 446 (99) 436 (102)
Number of patients who became hyperphosphatemic while PTH suppressed 66 71
Incidences of elevated Ca  P while PTH suppressed (per 1000 patient-day) 153 (33.9) 170 (39.8)
Number of patients with elevated Ca  P while PTH suppressed 43 43
Incidences of decreased Ca  P (50) while PTH suppressed (per 1000 patient-day) 507 (112.5) 394 (92.3)
Number of patients with decreased Ca  P (50) while PTH suppressed 71 70
calcemia and/or elevated Ca  P product between the phorus, such as paricalcitol, are also desirable in terms
of suppressing PTH with a decreased incidence of hyper-subgroup analysis and the multicenter analysis is an in-
teresting observation and may reflect the peculiarities of calcemia and/or elevations in the Ca  P product.
We would like to emphasize that the study designtreatment at a single center. The multicenter nature of
this study should negate any such peculiarities. of this comparative analysis was reflective of the dose-
reactive practice used by nephrologists in the early toThe importance of finding hypercalcemia and/or ele-
vated Ca  P product is further appreciated if one con- mid-1990s, whereby vitamin D administration was ad-
justed in order to reduce or avoid incidences of hypercal-siders that the development of hypercalcemia is more
likely to occur when PTH levels are rapidly lowered cemia and elevated Ca P product resulting from treat-
ment. Such an approach favored a slow and steadyand/or suppressed to levels below those considered to
be therapeutic. In this regard, recent long-term studies methodology that resulted in a gradual decline of PTH
with what were considered “manageable” occurrenceshave shown that paricalcitol dosed at a 3:1 ratio may be
as effective in suppressing PTH but may significantly of hypercalcemia and elevated Ca  P. At that time,
management of hypercalcemia commonly consisted ofminimize the hypercalcemia [22]. Yet, the present study
demonstrates that in subjects receiving paricalcitol there reducing or withholding vitamin D therapy until calcium
and phosphorus levels returned to clinically acceptablewas a lower incidence of sustained hypercalcemia and/or
elevated Ca  P product while PTH had decreased to ranges as there were no safe and effective noncalcium-
containing phosphate binders available. Furthermore,the target range more rapidly than in those receiving
calcitriol (Table 5). The exact dosing in relation to prior the acceptable levels of calcium and Ca  P allowed in
the study (11.5 mg/dL and 75 mg/dL, respectively), whichcalcitriol usage may not be as high as the 4:1 ratio em-
ployed in this study. Lower doses may be just as effective were at that time considered acceptable for initiating
vitamin D therapy, certainly fall outside of what is cur-but with fewer accompanying side effects.
Recent understanding of the role of calcium and phos- rently considered suitable as a goal of patient manage-
ment. The dose of vitamin D necessary to effectivelyphorous in the morbidity and mortality in patients with
chronic renal failure [17] has led to important refine- treat a particular patient’s PTH level often induced an
excessively high calcium level. In cases where vitamin Dments in the therapeutic approach toward hyperparathy-
roidism. These analyses suggest that increased mortality treatment was insufficient, the outcome for such patients
was further progression of their hyperparathyroidismis related to the severity of hyperphosphatemia and ele-
vation of CaP [29]. Calcitriol, especially in conjunction and, in extreme cases, surgical parathyroidectomy. The
concomitant occurrence of hypercalcemia or elevatedwith calcium-containing phosphate binders, greatly in-
creases the risk for hypercalcemia, hyperphosphatemia, Ca  P was a rate-limiting factor rather than a true
measure of a patient’s ability to respond to treatment.and increased Ca P [13, 19]. These disturbances, in turn,
can cause soft tissue and vascular calcifications and con- The shortcoming of this approach was the creation of a
significant subset of patients who were considered “re-tribute to increased mortality and cardiovascular mor-
bidity [18, 29, 30]. Thus, recent efforts have focused on fractory” to vitamin D treatment.
Other studies have revealed the critical importancedeveloping therapies that do not precipitate an increase
in overall calcium load. This has included the introduc- of rapid reduction of PTH levels in order to preserve
remaining vitamin D receptor function [30–32] and thetion of the noncalcium-containing phosphate binder sev-
elamer hydrochloride [20]. Analogues of calcitriol that value of early identification of true “responders” versus
potential nonresponders. ESRD patients commonly ex-have less effect on the absorption of calcium and phos-
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hibit a lack of vitamin D receptors in the more severe which suggest that paricalcitol might be safer. The pari-
and nodular forms of parathyroid hyperplasia. Coupled calcitol patients tended to experience a greater number
with the increasing risks of extraosseous calcification, it is of days in the optimal range of PTH than did patients
necessary in clinical practice to promptly and accurately in the calcitriol group. In comparison to the calcitriol-
identify which patients will respond to vitamin D treat- treated patients, paricalcitol patients received fewer days
ment [30, 33, 34]. of study drug treatment, experienced fewer incidences
Bearing these issues in mind, results for this compara- of hypercalcemia while in the therapeutic range, and
tor trial are interesting and relevant in that they reflect experienced fewer incidences of elevated Ca  P while
the subtle shift from the reactive modalities of calcitriol in this range. In addition, the paricalcitol patients experi-
therapy to the interactive regimen made possible by a
enced greater incidences of decreased Ca  P (50)selective analog such as paricalcitol. While the primary
while in the therapeutic range. To emphasize the impor-endpoint of this study (single incidence of hypercalcemia
tance of these findings, one must consider that these resultsand/or elevated Ca  P) failed to differentiate paricalci-
were achieved without protocol-specified adjustments intol from calcitriol, this end point was ultimately short-
the chronic use of phosphate binders and that serumsighted in that it did not capture the clinical significance
phosphorus was controlled solely with the use of calcium-of overall maintenance of appropriate PTH levels. The
containing phosphate binders since sevelamer HCl wasclinical meaningfulness of a single episode of elevated
not yet available. Although these findings were not statis-calcium and/or Ca  P product, occurrences routinely
tically significant, they suggest a therapeutic advantageassociated with hemodialysis patients, is doubtful. As
evidenced by a secondary, and perhaps more meaningful, to the use of paricalcitol. It should be noted that PTH
end point (the incidence of hypercalcemia for two con- concentrations are used as a surrogate marker of bone
secutive laboratory draws and/or Ca  P  75 for four disease. Thus, PTH suppression to a target level is pre-
consecutive laboratory draws), there was a statistically sumed evidence for therapeutic efficacy. Clearly, further
significant difference (P  0.008) in the number of pa- studies that include the use of bone histomorphometry
tients who experienced prolonged hypercalcemia and should be designed to confirm this therapeutic advantage.
increased Ca  P product (Table 4). Given the difference in our understanding and approach
In addition to this crucial finding, paricalcitol reduced to the treatment of hyperparathyroidism today compared
serum levels of PTH much more rapidly than calcitriol.
to when this protocol was designed years ago, it is power-Patients in the paricalcitol treatment group achieved a
ful to note that these results distinguish a significantmean reduction in PTH of 50% at week 15 versus
difference in outcomes in patients treated with paricalci-week 23 for calcitriol-treated patients. This finding was
tol as opposed to calcitriol. Such a study was difficult toreinforced by a Kaplan-Meier analysis that indicated the
design and clearly would not be conducted in the samemedian number of days to achieve a 50% reduction
fashion today. Nevertheless, the results of this study re-was 87 for paricalcitol patients versus 108 for calcitriol
inforce the current trends demonstrated in clinical prac-patients, a statistically significant finding (P  0.025).
tice (i.e., the desire to reduce PTH levels expeditiouslyWhile of potential clinical benefit, the rapid reduction
while maintaining patient safety and the maintenance ofof PTH exhibited by the paricalcitol group in this study
increased the difficulty of making an adequate compari- PTH levels within a clinically acceptable range). Further-
son to calcitriol. The dose-increase criteria resulted in more, noncalcium-containing phosphate binders were
PTH levels100 pg/mL, with some patients having PTH not available, thus differences observed in the incidence
concentrations as low as 10 to 20 pg/mL. These results of hypercalcemia and/or elevated Ca  P product oc-
were well below the target range and are actually below curred with both groups receiving similar doses of cal-
the normal range for healthy subjects. Dosing criteria fur- cium containing binders to control serum phosphorus
ther required that no dose reduction could take place until concentrations. The incidence of hypercalcemia and ele-
two consecutive PTH results were 100 pg/mL. Physi- vated Ca  P product may be different with the use of
ologically, when PTH is oversuppressed (100 pg/mL),
the newer noncalcium-containing phosphate binders.
the risk of hypercalcemia is greatly increased. Yet pari-
The therapeutic advantage of paricalcitol demon-calcitol-treated patients experienced significantly fewer
strated by this study is consistent with studies in experi-episodes of sustained hypercalcemia and/or elevated
mental animals demonstrating that the administration ofCa  P compared to calcitriol-treated patients, clearly
paricalcitol can result in suppression of PTH withoutindicating a therapeutic advantage over calcitriol.
increasing the intestinal vitamin D receptor [24]. TheAnalyzing the results in terms of achieving an optimal
lack of increased expression of intestinal vitamin D re-PTH concentration (100 to 300 pg/mL) allows for a more
ceptor could limit the gastrointestinal absorption of cal-complete evaluation of the effectiveness of therapy.
There were several differences between the two groups, cium and phosphorus [23]. In addition, calcitriol appears
Sprague et al: Paricalcitol vs. calcitriol in secondary hyperparathyroidism1490
17. Block GA, Hulbert-Shearon TE, Levin NW, et al: Associationto be more potent than paricalcitol in mobilizing calcium
of serum phosphorus and calcium  phosphorus product with
resorption from bone in vivo [23, 25] (abstract; Slatopol- mortality risk in chronic hemodialysis patients: A national study.
Am J Kidney Dis 31:607–617, 1998sky E et al, J Am Soc Nephrol 11:583A, 2000) and in
18. Goodman WG, Goldin J, Kuizon BD, et al: Coronary arteryvitro [26]. Further studies should seek to elicit the differ-
calcification in young adults with end stage renal disease undergo-
ences of vitamin D analogs through studies of their mech- ing dialysis. N Engl J Med 342:1478–1483, 2000
19. Mazhar RA, Johnson RJ, Gillen D, et al: Risk factors and mortal-anism of actions including gastrointestinal absorption
ity associated with calciphylaxis in end-stage renal disease. Kidneyand bone resorption.
Int 60:324–332, 2001
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